Valion Bio
Manufacturing · Texas, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
1305 E Houston St Bldg 1 Ste 311, San An...Phone Number
(888) 276-6888Website
www.valionbio.comRevenue
-Stock Symbol
VBIOIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About Valion Bio
Valion Bio is a late-stage biopharmaceutical company focused on developing biologic therapies that activate innate immune pathways for cytoprotection and immune modulation. The companys lead candidate, Entolimod, is a Toll-like receptor 5 agonist with a long development history, supported by regulatory designations such as FDA Fast Track and Orphan Drug status, and ongoing engagement with U.S. government agencies for potential inclusion in the Strategic National Stockpile. Valion Bio is also advancing Entolasta, a next-generation TLR5 agonist, while targeting applications in oncology supportive care, including neutropenia. In addition, its wholly owned subsidiary, Velocity Bioworks, operates as a contract development and manufacturing organization, supporting both internal production and third-party biotechnology clients.Explore more
Valion Bio Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Valion Bio your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on Valion Bio recently announced quarterly report
Valion Bio, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at Valion Bio
Funding: Get notified immidiatlly once Valion Bio has new funding data
Product Launch: Get notified when Valion Bio launches new products
Check if Valion Bio has recently received funding, and reach out quickly before it becomes old news!
Click to see if Valion Bio had a recent Job posting/layoffs
Check out if Valion Bio is spiking on competitors!
Recommended Actions
Reach out to Masked Content who joined Valion Bio as Masked Content
Find more new buyers
Company Profile Activity
Activity Insights
Valion Bio is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Valion Bio is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Valion Bio.
Most Recent Scoops
Person-Based
Governmental Affairs & Regulation, Regulations
Person-Based
Governmental Affairs & Regulation, Regulations
Person-Based
Pharmaceuticals, Clinical Operations
Person-Based
Partnership, Research & Development
Person-Based
Bioengineering, Pharmaceuticals
Valion Bio News & Media
World-Premier Cancer Center Sheba Medical Center Selects Entolimod for Clinical Trial, Potentially Expanding Valion Bio into the Multi-Billion-Dollar Neutropenia Market
Sheba Medical Center, which is ranked the #7 hospital in the world, has chosen to evaluate and fund a trial of Valion Bio's Entolimod in cancer patients, creating a second clinical development pathway beyond Acute Radiation Syndrome. Highlights Independent Validation — Sheba Medical...Valion Bio Advances Integrated Biodefense and Immunology Platform Through Continued Government Engagement, Domestic Manufacturing and Oncology Expansion
Strategic execution across multiple initiatives positions the Entolimod platform to pursue opportunities in government preparedness, domestic biomanufacturing and oncology supportive care SAN ANTONIO, July 14, 2026 /PRNewswire/ -- Valion Bio, Inc. (Nasdaq: VBIO) ("Valion Bio" or the...AFRRI/NIAID Designs Proprietary PBI-BM2.5 Protocol to Evaluate Valion Bio's (NASDAQ: VBIO) Entolimod as the First and Only Treatment for GI-ARS
AFRRI/NIAID partnership and validated animal models significantly derisk regulatory and commercial advancement of Company's lead candidate Positive momentum further positions Entolimod as a potential first and only treatment for GI-ARS, representing a multi-billion-dollar commercial...Valion Bio (NASDAQ: VBIO) Confirms U.S. House Armed Services Committee Initiative to Address Urgent Need for Radiation /Nuclear Countermeasures
Emanates from the FY27 NDAA process underway in the U.S. Congress Prioritizes radiation/nuclear countermeasures that are both prophylactic (radioprotectant) and therapeutic (radiomitigant) Follows Company's two recent briefings for senior DoW officials regarding its lead candidate,...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Valion Bio
Sign Up For FreeTo access detailed company insights
Valion Bio is a late-stage biopharmaceutical company focused on developing biologic therapies that activate innate immune pathways for cytoprotection and immune modulation. The companys lead candidate, Entolimod, is a Toll-like receptor 5 agonist with a long development history, supported by regulatory designations such as FDA Fast Track and Orphan... Read More
